A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD
NCT ID: NCT00308191
Last Updated: 2008-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
128 participants
INTERVENTIONAL
2006-04-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02238119
Study in Subjects Greater Than 40 Years of Age With COPD
NCT00507234
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239421
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
NCT00139932
Tiotropium and Salmeterol PK Study in COPD Patients
NCT00673478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Formoterol Fumarate
Tiotropium Bromide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current or prior history of cigarette smoking
Exclusion Criteria
* Significant condition or disease other than COPD
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dey
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dey L.P.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Phoenix, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
Sepulveda, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Tamarac, Florida, United States
Research Site
Gainesville, Georgia, United States
Research Site
Auburn, Maine, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Livonia, Michigan, United States
Research Site
St Louis, Missouri, United States
Research Site
Liverpool, New York, United States
Research Site
Rochester, New York, United States
Research Site
Medford, Oregon, United States
Research Site
Collegeville, Pennsylvania, United States
Research Site
El Paso, Texas, United States
Research Site
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 Apr;102(4):479-87. doi: 10.1016/j.rmed.2007.12.019. Epub 2008 Feb 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201-070
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.